Clinical Trial Results:
A phase II, multicentre, open-label, single arm, extension study of maintenance
treatment with subcutaneous homoharringtonine (HHT) as a single agent in
patients with chronic myeloid leukemia (CML) who received HHT in study HHT-CML/
INTL/04.2 and have achieved a complete hematological response (CHR)
or returned to chronic phase.
Summary
|
|
EudraCT number |
2005-000814-11 |
Trial protocol |
GB |
Global completion date |
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
21 Mar 2021
|
First version publication date |
21 Mar 2021
|
Other versions |
|
Summary report(s) |
Stragen France - HHT-CMLINTL04.3_Justification |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.